Completely agree. The reaction after is probably different. I'm tired of watching these p1, p2 companies getting 5x, 10x returns with positive results on these small niche markets, when cydy is so close to drug approval in a larger market with zilch. The announcement wakes up the rest of the biotech community, most asked on seekalpha have never heard of it, even those covering Gilead. Nope, never heard of CytoDyn.